GlassScriptPhysician profile
Mark W Shirey
NPI 1740274885
$16,291.48
in general payments reported to CMS, 2019-2025
19 companies · $233 in 2025
The $233 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,337 · 2020: $1,884 · 2021: $10K · 2022: $766 · 2023: $473 · 2024: $171 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Entertainment: $58.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.36 |
| Entertainment | $58.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $11,463.01 | 2020-2025 | Total30, Precision 1 |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $2,439.63 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $431.10 | 2022-2025 | Infuse, Miebo |
| Optos, INC. | $243.41 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Glaukos Corporation | $231.12 | 2020-2021 | |
| Coopervision INC. | $204.30 | 2019-2023 | Myday Contact Lens |
| Johnson & Johnson Surgical Vision, INC. | $181.93 | 2022 | |
| Apellis Pharmaceuticals, INC. | $179.11 | 2023-2025 | Syfovre |
| Maculogix, INC. | $140.25 | 2020 | |
| Novartis Pharmaceuticals Corporation | $125.00 | 2019 | |
| Allergan, INC. | $124.74 | 2022 | |
| Aerie Pharmaceuticals, INC. | $120.54 | 2021 | |
| Sun Pharmaceutical Industries INC. | $113.87 | 2020-2023 | Cequa |
| Dompe US, INC. | $85.66 | 2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $62.91 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Topcon Healthcare, INC. | $47.36 | 2020 | |
| Oyster Point Pharma, INC. | $44.80 | 2022 | |
| Derma Sciences, INC. | $31.82 | 2019 | |
| Abbvie INC. | $20.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Shirey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.